How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of pulsed field ablation for atrial fibrillation

    Closed for comments This consultation ended on at   Request commenting lead permission

    Existing assessments of this procedure

    No existing guidelines were identified in standard searches. Topic experts corroborated that there are no guidelines specific to PFA yet, but noted the following:

    • Heart Rhythm Society position statement (North America): "In the context of regulatory approval of PFA by multiple competent authorities across the world (including the FDA), HRS believes that this novel treatment modality should be made available to patients based on the best clinical judgment of the treating physician. Controlled clinical trials and real-world evidence registries have demonstrated that PFA is a safe and effective treatment for arrhythmia conditions including AF. Adoption of this technology could lead to improved cardiovascular outcomes and quality of life with reduced costs associated with recurrent hospitalizations and the need for additional procedures. The Society recommends that payors apply the same coverage criteria for PFA as those established for thermal ablation of AF."

    • Section 6.2.3. of a consensus statement from the US Heart Rhythm Society and its EU, Asia and Pacific, and Latin America equivalents describes mostly preclinical data but includes information on differences in properties of PFA between different manufacturers which may affect safety and efficacy.

    Comments panel open